Kodiak Sciences (NASDAQ:KOD) Stock: Insider Bros. Advisors Lp Baker Buys 160,658 Shares

Kodiak Sciences Inc. (NASDAQ:KOD) Director Bros. Advisors Lp Baker acquired 160,658 shares of the firm’s stock in a transaction on Wednesday, November 4th. The stock was bought at an average price of $98.51 per share, for a total transaction of $15,826,419.58. Following the completion of the acquisition, the director owned 20,343,130 shares of the company’s stock, valued at approximately $2,004,001,736.30. The trade was a 0.80% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.

Bros. Advisors Lp Baker also recently made the following trade(s):

• On Thursday, November 5th, Bros. Advisors Lp Baker bought 86,432 shares of Kodiak Sciences stock. The shares were purchased at an average price of $98.51 per share, for a total transaction of $8,514,416.32.
• On Monday, September 28th, Bros. Advisors Lp Baker purchased 807,840 shares of Kodiak Sciences stock. The shares were acquired at an average cost of $72.57 per share, for a total transaction of $58,624,948.80.
• On Monday, September 28th, Bros. Advisors Lp Baker acquired 418,323 shares of Kodiak Sciences stock. The shares were bought at an average price of $83.58 per share, for a total transaction of $34,963,436.34.
• On Tuesday, September 29th, Bros. Advisors Lp Baker bought 33,726 shares of Kodiak Sciences stock. The stock was purchased at an average cost of $85.05 per share, for a total transaction of $2,868,396.30.
• On Monday, September 28th, Bros. Advisors Lp Baker purchased 681,866 shares of Kodiak Sciences stock. The stock was acquired at an average price of $88.77 per share, for a total transaction of $60,529,244.82.

Kodiak Sciences Price Performance

KOD stock traded up $8.28 during trading on Friday, reaching $99.30. 1,038,739 shares of the company were exchanged, compared to its average volume of 1,128,011. Kodiak Sciences Inc. has a twelve month low of $15.83 and a twelve month high of $104.00. The company has a 50-day moving average of $68.36 and a two-hundred day moving average of $43.32. The company has a market capitalization of $6.24 billion, a price-to-earnings ratio of -23.70 and a beta of 2.02.

Kodiak Sciences (NASDAQ:KOD) last posted its earnings results on Thursday, August 13th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.09). On average, analysts forecast that Kodiak Sciences Inc. will post -3.97 EPS for the current year.

Hedge Funds Weigh In On Kodiak Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Arizona State Retirement System grew its position in shares of Kodiak Sciences by 6.9% during the 2nd quarter. Arizona State Retirement System now owns 8,533 shares of the company’s stock worth $332,000 after buying an additional 554 shares during the period. V Square Quantitative Management LLC bought a new stake in shares of Kodiak Sciences in the 1st quarter valued at $26,000. EverSource Wealth Advisors LLC increased its stake in shares of Kodiak Sciences by 94.5% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,927 shares of the company’s stock valued at $73,000 after acquiring an additional 936 shares in the last quarter. KBC Group NV acquired a new position in shares of Kodiak Sciences during the 1st quarter valued at $39,000. Finally, Sterling Capital Management LLC lifted its position in shares of Kodiak Sciences by 850.0% during the 3rd quarter. Sterling Capital Management LLC now owns 1,311 shares of the company’s stock valued at $124,000 after acquiring an additional 1,173 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on KOD. Weiss Ratings lowered Kodiak Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, October 6th. Wall Street Zen upgraded Kodiak Sciences from a “strong sell” rating to a “sell” rating in a research report on Sunday, October 4th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $112.00 price objective on shares of Kodiak Sciences in a research note on Monday, September 28th. JPMorgan Chase & Co. upped their target price on Kodiak Sciences from $56.00 to $66.00 and gave the company an “overweight” rating in a report on Monday, August 3rd. Finally, The Goldman Sachs Group initiated coverage on shares of Kodiak Sciences in a research report on Wednesday, September 30th. They set a “neutral” rating and a $103.00 target price for the company. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Kodiak Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.71.

About Kodiak Sciences

Kodiak Sciences Inc (NASDAQ: KOD) is a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases. The company’s research centers on therapies designed to address conditions that can cause vision loss, including diabetic macular edema, neovascular age-related macular degeneration and retinal vein occlusion.

Kodiak’s proprietary Antibody Biopolymer Conjugate platform is designed to combine the targeting capabilities of antibody-based medicines with a biodegradable polymer intended to extend the duration of treatment in the eye.